Clinical Trials
27 trialsNCT03467516 2026-06-01
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Active not recruiting
NCT04728633 2026-05-06
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
Thomas Jefferson University
Phase 2 Active not recruiting
NCT05187884 2026-04-23
NADOM
St Vincent's Hospital, Sydney
Phase 2 Completed
NCT06414590 2026-04-14
Neoadjuvant Tebentafusp for Uveal Melanoma
Thomas Jefferson University
Phase 2 Recruiting
NCT01587352 2026-04-13
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT01979523 2026-04-13
Trametinib With or Without GSK2141795 in Treating Patients With Metastatic Uveal Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05170334 2026-04-06
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05524935 2026-04-01
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT07276386 2026-03-31
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT02068586 2026-03-16
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Thomas Jefferson University
Phase 2 Active not recruiting
NCT05907954 2026-03-16
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
IDEAYA Biosciences
Phase 2 Active not recruiting
NCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT06070012 2026-02-27
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
University of Pittsburgh
Phase 2 Recruiting
NCT03417739 2026-02-25
A Phase II Study of BVD-523 in Metastatic Uveal Melanoma
Dana-Farber Cancer Institute
Phase 2 Terminated
NCT06627244 2026-02-23
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
University of Miami
Phase 2 Recruiting
NCT02517736 2026-02-17
O-Mel-Sora
University Hospital, Caen
Phase 2 Completed
NCT04552223 2026-02-11
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
University of Miami
Phase 2 Completed
NCT04645680 2026-01-30
DIET
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06717126 2026-01-16
OCULE-01
iOnctura
Phase 2 Active not recruiting
NCT06121180 2025-12-04
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05282901 2025-11-24
PLUME
Institut Curie
Phase 2 Active not recruiting
NCT01473004 2025-11-14
SIR-Spheres® 90Y Microspheres Treatment of Uveal Melanoma Metastasized to Liver
Thomas Jefferson University
Phase 2 Completed
NCT03712904 2025-09-24
Stereotactic Body Radiation Therapy and Aflibercept in Treating Patients With Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated
NCT05308901 2025-07-25
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Providence Health & Services
Phase 2 Active not recruiting
NCT05315258 2025-07-17
TebeMRD
University of Oxford
Phase 2 Active not recruiting
NCT04720417 2025-07-15
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
Thomas Jefferson University
Phase 2 Terminated